Fractyl Health, Inc. - Common Stock (GUTS)

NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Fractyl Health, Inc. (“Fractyl” or the “Company”) (NASDAQ: GUTS) and certain officers.   The class action, filed in the United States District Court for the Southern District of New York, and docketed under 26-cv-07167, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fractyl securities between January 13, 2025 and January 29, 2026, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Fractyl Health, Inc. ("“Fractyl” or the “Company”) (NASDAQ: GUTS) and reminds investors of the October 20, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you purchased or acquired Fractyl securities between January 13, 2025 and January 29, 2026 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at investigations@bespc.com or by telephone at (212) 355-4648.

Two named officers of Fractyl Health, Inc. — Co-Founder and CEO Harith Rajagopalan and former CFO Lisa A. Davidson — face Section 20(a) control person claims over allegedly overstated Revita DMR efficacy data, after GUTS shares lost approximately 74.86% of their value across two trading days.

If you purchased or acquired Fractyl securities between January 13, 2025 and January 29, 2026 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at investigations@bespc.com or by telephone at (212) 355-4648.

NEW YORK CITY, NY / ACCESS Newswire / October 16, 2026 / Levi & Korsinsky, LLP alerts investors in Fractyl Health, Inc. (NASDAQ:GUTS) that a securities class action has been filed on behalf of shareholders who purchased securities between January 13, 2025 and January 29, 2026. Find out if you may qualify to recover losses. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or ☎(212) 363-7500.

REMAIN-1 met its six-month co-primary endpoint with high statistical significance (p=0.0023; mITT population); demonstrated 80% retention of GLP-1 induced weight loss vs 67% for sham

If you purchased or acquired Fractyl securities between January 13, 2025 and January 29, 2026 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at investigations@bespc.com or by telephone at (212) 355-4648.

NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Fractyl Health, Inc. (“Fractyl” or the “Company”) (NASDAQ: GUTS) and certain officers.   The class action, filed in the United States District Court for the Southern District of New York, and docketed under 26-cv-07167, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fractyl securities between January 13, 2025 and January 29, 2026, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

Wall Street's reassessment of Fractyl Health was swift: Morgan Stanley cut its price target from $8.00 to $2.00 and downgraded GUTS to Equal-weight, while Canaccord Genuity Canaccord Genuity addressed concerns surrounding an “outlier site" in the Revita DMR data.

NEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Fractyl Health, Inc. (“Fractyl” or the “Company”) (NASDAQ: GUTS) of the October 20, 2026 deadline involving a securities fraud class action lawsuit commenced against the Company.

Allegations center on operational failures at one of six REMAIN-1 Midpoint Cohort clinical sites, which the complaint contends skewed Revita DMR weight maintenance data that Fractyl Health promoted to investors.

NEW YORK CITY, NY / ACCESS Newswire / October 9, 2026 / Levi & Korsinsky, LLP notifies investors in Fractyl Health, Inc. (NASDAQ:GUTS) that a securities class action has been filed on behalf of shareholders who purchased securities between January 13, 2025 and January 29, 2026. Submit your information now. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or ☎(212) 363-7500.

If you purchased or acquired Fractyl securities between January 13, 2025 and January 29, 2026 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at investigations@bespc.com or by telephone at (212) 355-4648.

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Fractyl Health, Inc. (“Fractyl” or the “Company”) (NASDAQ: GUTS) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 26-cv-07167, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Fractyl securities between January 13, 2025 and January 29, 2026, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Fractyl Health, Inc. (“Fractyl” or the “Company”) (NASDAQ: GUTS) between January 13, 2025 and January 29, 2026, inclusive.

NEW YORK CITY, NY / ACCESS Newswire / October 2, 2026 / Levi & Korsinsky, LLP reminds purchasers of Fractyl Health, Inc. (NASDAQ:GUTS) securities of a pending securities class action brought on behalf of investors who purchased shares between January 13, 2025 and January 29, 2026. See if you could be eligible to recover. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or ☎(212) 363-7500.

If you purchased or acquired Fractyl securities between January 13, 2025 and January 29, 2026 and would like to discuss your legal rights, contact Bragar Eagel & Squire partners Brandon Walker or Melissa Fortunato by email at investigations@bespc.com or by telephone at (212) 355-4648.

NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Fractyl Health, Inc. (“Fractyl” or the “Company”) (NASDAQ: GUTS) of the October 20, 2026 deadline involving a securities fraud class action lawsuit commenced against the Company.